Home » Stocks » CGIX

Cancer Genetics, Inc. (CGIX)

Stock Price: $5.63 USD 0.38 (7.24%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $5.82 +0.19 (3.38%) Mar 5, 7:53 PM
Market Cap 59.47M
Revenue (ttm) 6.33M
Net Income (ttm) -4.53M
Shares Out 2.33M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $5.63
Previous Close $5.25
Change ($) 0.38
Change (%) 7.24%
Day's Open 5.36
Day's Range 5.00 - 5.67
Day's Volume 506,992
52-Week Range 1.92 - 17.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Rober...

GlobeNewsWire - 2 weeks ago

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, toda...

GlobeNewsWire - 3 weeks ago

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, toda...

Benzinga - 3 weeks ago

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above e...

Other stocks mentioned: USNA, ABCL, AZRX
InvestorPlace - 3 weeks ago

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's...

GlobeNewsWire - 1 month ago

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, toda...

GlobeNewsWire - 1 month ago

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, toda...

GlobeNewsWire - 1 month ago

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Robert...

PRNewsWire - 3 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX"...

GlobeNewsWire - 3 months ago

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, anno...

GlobeNewsWire - 4 months ago

Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-on...

GlobeNewsWire - 4 months ago

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, ...

GlobeNewsWire - 4 months ago

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology service...

PRNewsWire - 5 months ago

MUMBAI, India and LONDON, Sept. 28, 2020 /PRNewswire/ -- A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has...

PRNewsWire - 5 months ago

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...

GlobeNewsWire - 5 months ago

RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, t...

GlobeNewsWire - 6 months ago

RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology servic...

PRNewsWire - 6 months ago

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

PRNewsWire - 6 months ago

NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc.

Business Wire - 6 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Newsfile Corp - 6 months ago

Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.

PRNewsWire - 6 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc.

Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc.

Benzinga - 6 months ago

Cancer Genetics (NASDAQ: CGIX) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX.

24/7 Wall Street - 6 months ago

Cancer Genetics Inc. (NASDAQ: CGIX) shares more than doubled on Monday after the company announced a merger with StemoniX.

InvestorPlace - 6 months ago

Cancer Genetics' news of a merger with major drug developer StemoniX has CGIX stock skyrocketing higher on Monday morning. The post Cancer Genetics News: Why CGIX Stock Is Rocketing Today appe...

GlobeNewsWire - 6 months ago

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

GlobeNewsWire - 6 months ago

RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, an...

24/7 Wall Street - 8 months ago

Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings a...

Other stocks mentioned: AHCO, ARAV, GNUS, NOVA, PAYS, RMBL
GlobeNewsWire - 8 months ago

RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, to...

GlobeNewsWire - 1 year ago

RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-...

GlobeNewsWire - 1 year ago

RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced st...

GlobeNewsWire - 1 year ago

Note Payment Received from Interpace Diagnostics Group, Inc.

GlobeNewsWire - 1 year ago

RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced tha...

GlobeNewsWire - 1 year ago

RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced st...

Benzinga - 1 year ago

Cancer Genetics (NASDAQ: CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.

About CGIX

Cancer Genetics, through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervi... [Read more...]

Industry
Biotechnology
IPO Date
Apr 5, 2013
CEO
John Roberts
Employees
110
Stock Exchange
NASDAQ
Ticker Symbol
CGIX
Full Company Profile

Financial Performance

In 2019, CGIX's revenue was $7.31 million, an increase of 48.11% compared to the previous year's $4.93 million. Losses were -$6.71 million, -67.07% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CGIX is 3.00, which is a decrease of -46.71% from the latest price.

Price Target
$3.00
(-46.71% downside)